Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE(®)) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Phil...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Anthony, Franklin, Janet L., Chia, Victoria M., Arrindell, Deborah, Kormany, William, Wright, Jacqueline, Parson, Mandy, Amouzadeh, Hamid R., Choudhry, Jessica, Joseph, Guiandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475509/
https://www.ncbi.nlm.nih.gov/pubmed/30565020
http://dx.doi.org/10.1007/s40264-018-0760-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475509/
https://www.ncbi.nlm.nih.gov/pubmed/30565020
http://dx.doi.org/10.1007/s40264-018-0760-1

Ejemplares similares